Ivermectin Medical Valley

Ivermectin, the active ingredient in Ivermectin Medical Valley, is an antiparasitic (macrocyclic lactone) presented as an oral formulation for systemic use. It treats infections such as onchocerciasis, strongyloidiasis, scabies and pediculosis in appropriate patients.

GNH USA supplies Ivermectin Medical Valley as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin acts on a range of parasitic infections by targeting neural pathways of the organisms. - Onchocerciasis: reduces microfilarial load and prevents disease progression. - Strongyloidiasis: eradicates intestinal nematodes and prevents hyperinfection. - Scabies: eliminates Sarcoptes scabiei mites and resolves skin lesions. - Pediculosis: kills head lice and nits, reducing infestation.

Ivermectin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools occurring shortly after dosing. - Abdominal pain: cramping or discomfort in the stomach area. - Pruritus: mild skin itching. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic injury: signs of liver dysfunction such as jaundice. - Neutropenia: low white‑blood‑cell count increasing infection risk. - Anaphylaxis: acute allergic reaction with breathing difficulty. - Visual disturbances: blurred vision or ocular pain. - Severe skin rash: extensive erythema or exfoliative dermatitis.

Before prescribing Ivermectin, clinicians should consider several safety aspects. - Assess hypersensitivity: avoid use in patients with known allergy to ivermectin or excipients. - Evaluate liver function: dose adjustment may be required in moderate to severe hepatic impairment. - Monitor for Loa loa infection: high microfilaremia can precipitate severe neurologic reactions. - Review concomitant medications: consider potential pharmacokinetic interactions. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Ivermectin may interact with other medicines, requiring attention to the interaction strength.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin): may markedly reduce ivermectin exposure. - Warfarin: concurrent use can increase bleeding risk. - Other neurotoxic antiparasitics: combined use may enhance neurotoxicity.

Moderate Interactions (Monitor Closely): - Macrolide antibiotics (e.g., erythromycin): may raise ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil): can increase systemic exposure. - Antifungal azoles (e.g., ketoconazole): may modestly increase concentrations.